Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060090 | 0.92 | PTGDR2 (0.50) | L3MBTL1PTGDR2CA5AFABP4GAA | |
| SCHEMBL1059756 | 0.88 | PTGDR2 (0.55) | PTGDR2CA5AGAATBXA2RPTGDR | |
| SCHEMBL3629305 | 0.86 | PTGDR2 (0.49) | PTGDR2CA5AGAATBXA2RPTGDR | |
| SCHEMBL155869 | 0.83 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL3622456 | 0.82 | PTGDR2 (0.47) | PTGDR2CA5AGAATBXA2RPTGDR | |
| SCHEMBL1057069 | 0.80 | PTGDR2 (0.59) | PTGDR2CA5AGAATBXA2RPTGDR | |
| SCHEMBL1059554 | 0.79 | PTGDR2 (0.62) | PTGDR2GAATBXA2RPTGDR | |
| SCHEMBL140820 | 0.78 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL1051736 | 0.78 | PTGDR2 (0.56) | PTGDR2GAATBXA2RPTGDR | |
| SCHEMBL1059636 | 0.77 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245022-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009108720-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | claimed |
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | L3MBTL1 4353/4885PTGDR2 2/4885CA5A 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.